Related Experiment Video
Updated: Dec 10, 2025

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
Malignant Priapism - What Do We Know About It?
Dragos Marcu1,2, Lucian Iorga1, Dan Mischianu1,2,3
1Clinic of Urology, University Emergency Central Military Hospital "Dr. Carol Davila", Bucharest, Romania.
Abstract:
Malignancy as an etiological factor involved in priapism pathogenesis is rare. Malignant priapism (MP) can arise as a result of penile tumor invasion, either from primary penile tumors or from metastatic penile tumors, or due to hematological malignancies. Non-urological penile metastases are associated with significant worse prognosis compared to urological penile metastases, the appearance of priapism in such cases affecting even more the prognosis and the survival of these patients. Patients diagnosed with hematological malignancies and priapism present significant higher survival rates compared to those who develop MP in the context of a non-hematological malignancy, this being related to the fact that hematological malignancies are more sensitive to chemo- and radiotherapy. Most malignant priapism cases are ischemic; therefore the management should be based on the initial steps of the IP therapeutic protocol. Considering the trigger factor that has led to the priapic event specific oncologic treatment can be added as well.
Insights
Malignant priapism (MP) is rare, often linked to penile tumors or blood cancers. Hematological malignancies offer better survival rates for MP patients due to treatment sensitivity.
Area of Science:
- Oncology
- Urology
Background:
- Malignancy is a rare cause of priapism.
- Malignant priapism (MP) can result from primary penile tumors, metastatic penile tumors, or hematological malignancies.
- Non-urological penile metastases are associated with a worse prognosis than urological ones, with priapism further worsening outcomes.
Purpose of the Study:
- To review the role of malignancy in priapism pathogenesis.
- To compare prognoses based on the origin of penile metastases and type of malignancy.
- To outline management strategies for malignant priapism.
Main Methods:
- Literature review of malignant priapism cases.
- Analysis of prognostic factors including tumor origin and malignancy type.
- Review of current therapeutic protocols for priapism and oncologic treatments.
Main Results:
- Malignant priapism is uncommon, arising from various cancers.
- Hematological malignancies associated with priapism show higher survival rates than non-hematological ones, owing to treatment sensitivity.
- Most malignant priapism cases are ischemic.
Conclusions:
- Malignant priapism requires a management approach similar to ischemic priapism, with added oncologic-specific treatments.
- Prognosis varies significantly based on the type and origin of the malignancy.
- Early recognition and tailored treatment are crucial for improving patient outcomes.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Pulmonary Embolism I: Introduction
Angina II: Classification
Abnormal Proliferation
Peripheral Artery Disease IV: Nursing Management

